Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Oculis Announces Closing of Registered Direct Offering and Commencement of…
Raised gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares toIcelandic institutional andexistinginvestors Becomes second company dual-listed on NASDAQ U.S. and NASDAQ Iceland Main Market, trading under the symbol “OCS” beginning April 23, 2024 Oculis will ring the Nasdaq Iceland opening bell on April 23, 2024, at 9:30 GMT Phase 2b RELIEF trial of OCS-02 (Licaminlimab) in Dry Eye Disease (DED) remains on track to readout in Q2...
Nasdaq GlobeNewswire
22/04/2024
Curaleaf Completes Acquisition of Northern Green Canada
Integrating NGC's international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland. Integrating NGC's international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions inGermany, theUnited KingdomandPoland. "We are...
PR Newswire
22/04/2024
Waters Accelerates the Development of Gene-based Therapeutics with New…
"The pipeline of nucleic acid therapeutics continues to grow at a double-digit paceii as developers strive to submit new investigational drug filings and complete their first in-human trials. The new Waters GTxResolve Premier SEC Columns supports the growing demand for mRNA, lipid nanoparticle, and viral vector-based therapies with columns that are more robust and provide higher efficiency," said Erin Chambers, Vice President, Consumables and Lab Automation, Waters Corporation…
PR Newswire
22/04/2024
Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance…
Eitan Konstantino, PhD, a serial entrepreneur in the vascular device field, is the driving force behind Expanse ICE. "We've engineered the ICE catheter system to harness the aspiration power typical of a large bore catheter, but within the slender profile of a much smaller device," Dr. Konstantino said. Eitan Konstantino, PhD, a serial entrepreneur in the vascular device field, is the driving force behind Expanse ICE. "We've engineered the ICE catheter system to harness the…
PR Newswire
22/04/2024
Landmark New Publication: the Forgotten Biochemistry 101 of COVID-19
The glycan monomer sialic acid, ubiquitous on eukaryotic cell surfaces, serves as the initial attachment point to host cells for the COVID–19 virus—SARS–CoV–2—as well as for other coronaviruses. The virus can then slide over to ACE2 for cell entry. SARS–CoV–2 spike protein attaches particularly tightly to the dense sialic acid coatings on the trillions of red blood cells (RBCs), platelets and endothelial cells in the human adult. These interlaced attachments trigger the RBC aggregation…
PR Newswire
22/04/2024
U.S. Institute of Peace Opens Nominations for 2024 Women Building Peace Award
The nomination period will run until June 10, 2024. USIP invites organizations and people across the globe to take part in identifying and honoring exceptional women who have dedicated their lives to building peace. The awardee will be recognized at a ceremony in Washington, DC, and will receive a cash prize. The nomination period will run untilJune 10, 2024. USIP invites organizations and people across the globe to take part in identifying and honoring exceptional women who have dedicated...
PR Newswire
22/04/2024
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple…
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-upAll Patients Have Either Stabilized or Improved on Nasal Foralumab Treatment and No Patients Declined in Key Clinical MeasuresNEW YORK, April22, 2024(GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug...
Nasdaq GlobeNewswire
22/04/2024
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in…
BOSTON and LONDON, April22, 2024(GLOBE NEWSWIRE) --Centessa Pharmaceuticals plc(Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administered,...
Nasdaq GlobeNewswire
22/04/2024
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on…
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via telephone, please register...
Nasdaq GlobeNewswire
22/04/2024
Leo Cancer Care Teams up With World-Leading Carbon Ion Centre
A groundbreaking deal has been agreed with CNAO (National Center for Oncological Hadrontherapy) in Pavia, Italy. Marie® an upright patient positioning system combined with a vertical CT scanner, which will be placed in front of an existing fixed radiation beam with patients rotated slowly and smoothly to different beam angles as treatment is administered. A groundbreaking deal has been agreed with CNAO (National Center for Oncological Hadrontherapy) in Pavia,Italy. Marie® an upright patient...
PR Newswire
22/04/2024
Progesterone Therapy in Demand for Personalized Medicine: Market to Reach US$4.8…
Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19526 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19526 The progesterone market thrives because of the rising cases of breast cancer, AIDS, and amenorrhea and the adoption of progesterone in medicating the issues. Several researchers infer that progesterone and...
PR Newswire
22/04/2024
Super Generics Market Size Will Reach USD 128.62 Billion to 2031 - Revealed…
Download Free Report Sample Pages @https://www.insightaceanalytic.com/request-sample/2437 Download Free Report Sample Pages @https://www.insightaceanalytic.com/request-sample/2437 The Super Generics market encompasses an advanced category of generic drugs designed to offer additional benefits beyond traditional generics, such as enhanced efficacy, safety, or delivery mechanisms. This segment has been steadily growing, driven by factors including patent expirations of blockbuster drugs,...
PR Newswire
22/04/2024
Prescient Healthcare Group Announces the Appointment of Two New Members to Its…
Debbie Allman leads our global Commercial practice, focusing in particular on driving our growth in the US further. She is an accomplished commercial strategist with a broad range of experience in pharmaceutical commercialization and marketing. She started her career at AstraZeneca, holding numerous global and national (UK, Italy) marketing and sales roles over a 15-year period; in 2010, she began her consulting career by co-founding Strategic North, an insight-led brand strategy consultancy…
PR Newswire
22/04/2024
AIRS Medical Accelerates Global Expansion with MRI AI Solution SwiftMR™ Supply…
According to AIRS Medical, "RNZ proceeded to sign the final contract with high satisfaction after experiencing firsthand the improvement in image quality and increased productivity due to reduced scan times of over 10-year-old MRI scanner during the demo period." In particular, the company explained that the versatility of SwiftMR™, which can be used on various types of MRI scanner models as a standalone solution, played a significant role in securing the contract. According to AIRS…
PR Newswire
22/04/2024
Nexstim Receives NBS 6 System Order from Clinic in Florida, US
Press release, Helsinki, 22 April 2024 at 11 AM (EEST) Nexstim Receives NBS 6 System Order from Clinic in Florida, US Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from a new clinic customer located in Florida, Unites States.Launched in 2023 in the United States and Europe, the NBS 6 is a new Nexstim product generation that brings the usability of the Nexstim system to a new level. The NBS 6 is currently FDA-approved for the...
Nasdaq GlobeNewswire
22/04/2024
Transactions in Connection with Share Buy-back Program Genmab
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from April 15, 2024 to April 19, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
22/04/2024
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of…
TGCT is a type of tumour that affects the soft tissue lining of joints and tendons and is a highly debilitating disease often impacting large, important joints such as the knee, hip and ankle. TGCT is a type of tumour that affects the soft tissue lining of joints and tendons and is a highly debilitating disease often impacting large, important joints such as the knee, hip and ankle. TGCT is a chronic disease which often impacts patients throughout their lives. It seriously impacts quality...
PR Newswire
22/04/2024
Immunovia announces positive results from the model-development study for its…
Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d. The next-generation test includes high-performing protein biomarkers, making the test less reliant on CA19-9. This is a major achievement as around 10 percent of patients, including many patients of African ancestry, do not produce CA19-9, so the IMMray PanCan-d test could not be used in those patients. The results with the new test were achieved…
PR Newswire
22/04/2024
Orion Corporation: Managers' transactions – Veli-Matti Mattila
ORION CORPORATIONMANAGERS' TRANSACTIONS22 APRIL 2024 at 9.45 EEST Orion Corporation: Managers' transactions – Veli-Matti Mattila Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
22/04/2024
SNIPR Biome receives funding from CARB-X to support advancement of…
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation Copenhagen, April 22 2024 : SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, announces today that it has...
Nasdaq GlobeNewswire
22/04/2024
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
Press ReleaseNicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million (net revenue 1 €3.9 million) for first quarter 2024Nicox Group cash of €9.1 million on March 31, 2024 which finances the Company until at least November 2024 April 22, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the...
Nasdaq GlobeNewswire
22/04/2024
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in…
"Ipsen is an extraordinary company with a deep passion for serving patients, and we are excited to partner with them to expand their pipeline of innovative therapies," said Sergey Paushkin, Chief Scientific Officer at Skyhawk. "Our strategic partnership underscores our shared ambition to develop transformative medicines for people with rare neurological diseases for which there are no approved therapeutics." "Ipsen is an extraordinary company with a deep passion for…
PR Newswire
22/04/2024
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further…
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva ®approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and qualitySandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolioBasel, April 22, 2024– Sandoz, the global leader in generic and biosimilar...
Nasdaq GlobeNewswire
22/04/2024
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in…
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaborationFollowing development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disordersThis promising platform technology created by Skyhawk allows for the exploration of previously undruggable RNA targets with small molecules, expanding the disease target landscape...
Nasdaq GlobeNewswire
22/04/2024
Altri Comunicati